Sativex (r) recommended for adoption in ten countries, after the European mutual recognition regulatory process.
Sativex ® recommended for adoption in ten countries, after the European mutual recognition regulatory process. -Sativex ® is now available in the United Kingdom, Spain, Germany and Denmark. Other releases currently in preparation are Italy, Sweden, Austria and Czech Republic – expected release in Belgium, Finland, Iceland, Ireland, Luxembourg, Netherlands, Norway, Poland, Portugal and Slovakia from the end of 2012 Barcelona, Spain; Porton Down, UK, may 2012.- Almirall, S.A. (ALM) and GW Pharmaceuticals plc (AIM: GWP) have announced on Tuesday completed successfully a procedure of mutual recognition (PRM) for approval of Sativex ® mouth spray in the treatment of the symptoms of spasticity by multiple sclerosis (MS). After the success of the first presentations regulatory United Kingdom, Spain, Germany, Italy, Sweden Denmark, Austria and Czech Republic, presented a PRM for expanding the availability of Sativex ® in ten additional European countries. The PRM has now closed successfully and regulatory authorities of all the countries involved confirm Sativex ® meets the requirements for adoption. The countries included in this procedure, and which is expected that Sativex ® is approved are: Belgium, Finland, Iceland, Ireland, Luxembourg, Netherlands, Norway, Poland, Portugal and Slovakia. “For Almirall, this second European Sativex ® regulatory process successful completion is very good news and reinforces our commitment to expanding the availability of this innovative medication to a greater number of people with MS in Europe.” “Sativex ®...
Read More